These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15609146)

  • 21. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1325-31. PubMed ID: 19047253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing options to physician and retail dispensing.
    Gitlin M; Wilson L
    Am J Ind Med; 2007 Apr; 50(4):303-15. PubMed ID: 17370319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Kanavos P; Taylor D
    Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan.
    Lee YC; Huang KH; Huang YT
    Health Policy Plan; 2007 Nov; 22(6):427-35. PubMed ID: 17901065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuing effects of Medicare Part D on rural independent pharmacies who are the sole retail provider in their community.
    Radford A; Mason M; Richardson I; Rutledge S; Poley S; Mueller K; Slifkin R
    Res Social Adm Pharm; 2009 Mar; 5(1):17-30. PubMed ID: 19285286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis.
    Fretheim A; Håvelsrud K; MacLennan G; Kristoffersen DT; Oxman AD
    PLoS Med; 2007 Jul; 4(7):e232. PubMed ID: 17622192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--consequences for costs and availability.
    Rudholm N
    Health Policy; 2008 Aug; 87(2):258-63. PubMed ID: 18164509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical care in community pharmacies: practice and research in Denmark.
    Herborg H; Sørensen EW; Frøkjaer B
    Ann Pharmacother; 2007 Apr; 41(4):681-9. PubMed ID: 17389660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
    Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
    Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of the additional costs of dispensing workers' compensation prescriptions.
    Schafermeyer KW
    Res Social Adm Pharm; 2007 Mar; 3(1):123-36. PubMed ID: 17350561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Problems of national health insurance reimbursement revision, especially for laboratory tests].
    Mori M
    Rinsho Byori; 1995 Jul; 43(7):660-4. PubMed ID: 7674537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.